Risk of Malignancy in Bethesda Category III Thyroid Nodules with Nuclear Atypia: A Retrospective Study Based on Thyroidectomy Findings

• Ilkay Cinar

  University of Giresun, Turkey

Background: Thyroid nodules with cytological features of atypia of undetermined significance (AUS), particularly those with nuclear atypia, represent a diagnostic challenge due to their variable malignancy risk. The 2023 revision of the Bethesda System has refined AUS subcategories to improve malignancy risk stratification. The aim of this study was to evaluate the risk of malignancy in Bethesda Category III thyroid nodules with nuclear atypia by correlating cytological findings with post-thyroidectomy histopathological results.

Material and Methods: This retrospective observational study included 156 patients who underwent thyroid fine-needle aspiration cytology between 2020 and 2024 and were diagnosed with AUS featuring nuclear atypia. All patients subsequently underwent thyroidectomy. Malignancy rates were determined based on final histopathological diagnoses. Statistical analysis was performed using SPSS version 29.0, applying Chi-square and Fisher’s exact tests, with a significance threshold set at p < 0.05.

Results: The overall malignancy rate was 34.6%, increasing to 39.7% when NIFTP cases were included Fifty papillary carcinomas were identified, 28 of which were <1 cm. In 23 patients who received repeated AUS diagnoses, the malignancy rate reached 73.9% (p = 0.011). No statistically significant differences were found between benign and malignant groups in terms of age (p = 0.655), gender (p > 0.05), or lymphocytic thyroiditis (p = 0.3). The reported malignancy rates were exclusively to the cohort of Bethesda Category III nodules with nuclear atypia, which constituted the entire study population.

Conclusion: Thyroid nodules classified as AUS with nuclear atypia are associated with a higher-than-expected risk of malignancy, especially in cases with repeated AUS diagnoses. These findings underscore the importance of subclassifying AUS cases to improve risk stratification and guide clinical decision-making.

[1] Ali SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, Vielh P, VanderLaan PA. The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2023; 33(9): 1039-1044.

[2] Ryu YJ, Jung YS, Yoon HC, Hwang MJ, Shin SH, Cho JS, et al. Atypia of undetermined significance on thyroid fine needle aspiration: surgical outcome and risk factors for malignancy. Ann Surg Treat Res 2014; 86(3): 109-114.

[3] Ho AS, Sarti EE, Jain KS, Wang H, Nixon IJ, Shaha AR, et al. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid 2014; 24(5): 832-839.

[4] VanderLaan PA, Marqusee E, Krane JF. Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated FNA be the preferred initial approach? Am J Clin Pathol 2011; 135(5): 770-775.

[5] Straccia P, Rossi ED, Bizzarro T, et al. A meta-analytic review of the Bethesda System for Reporting Thyroid Cytopathology: has the rate of malignancy in indeterminate lesions been underestimated? Cancer Cytopathol 2015; 123: 713-722.

[6] Heller KS. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS): is there a correct answer? Thyroid 2014; 24(5): 787-788.

[7] Walters BK, Garrett SL, Aden JK, Williams GM, Butler-Garcia SL, Newberry TR, et al. Diagnostic lobectomy for Bethesda III thyroid nodules: pathological outcomes and risk factors for malignancy. Ann Otol Rhinol Laryngol 2021; 130: 1-8.

[8] Liu X, Wang J, Du W, Dai L, Fang Q. Predictors of malignancy in thyroid nodules classified as Bethesda category III. Front Endocrinol (Lausanne) 2022; 13: 806028.

[9] Crescenzi A, Palermo A, Trimboli P. Cancer prevalence in the subcategories of the indeterminate class III (AUS/FLUS) of the Bethesda system for thyroid cytology: a meta-analysis. J Endocrinol Invest 2021; 44: 1343-1351.

[10] Hassan I, Hassan L, Balalaa N, Askar M, Alshehhi H, Almarzooqi M. The incidence of thyroid cancer in Bethesda III thyroid nodules: a retrospective analysis at a single endocrine surgery center. Diagnostics (Basel) 2024; 14(10): 1026.

[11] Alwadi F, Alessa M, Alamer E, Alrabiah HF, Alaraifi A, Alsalem A, et al. Risk of malignancy in thyroid nodules Bethesda III subclassification into nuclear atypia and architectural atypia: a retrospective study. Saudi Med J 2025; 46(4): 425-428.

[12] Guerreiro SC, Tastekin E, Mourao M, Loureiro I, Eusebio R, Marques HP, et al. Impact of the 3rd edition of the Bethesda System for Reporting Thyroid Cytopathology on grey zone categories. Acta Cytol 2023; 67(6): 593-603.

[13] Hathi K, Rahmeh T, Munro V, Northrup V, Sherazi A, Chin CJ. Rate of malignancy for thyroid nodules with AUS/FLUS cytopathology in a tertiary care center: a retrospective cohort study. J Otolaryngol Head Neck Surg 2021; 50(1): 58.

• PDF

• Original Research Articles

Copyright (c) 2026 Ilkay Cinar

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.